Cargando…

Adjudicating the logistics of COVID-19 vaccine boosters from a global perspective

The emergence of the novel SARS-CoV-2 variants has led to the advocation of COVID-19 vaccine boosters by many countries. The reasons cited for the booster vaccination, such as waning immunity, immune escape due to viral evolution and suboptimal responses in immunocompromised individuals, need to be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Priyanka, Choudhary, Om Prakash, Singh, Indraj
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Coronavirus – Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986300/ https://www.ncbi.nlm.nih.gov/pubmed/35026127 http://dx.doi.org/10.1080/21645515.2021.2020572

Ejemplares similares

Vaccination certificate: An initiative to mitigate COVID-19 waves in India?
por: Choudhary, Om Prakash, et al.
Publicado: (2021)

Third wave of COVID-19 in India: Prediction and preparedness
por: Choudhary, Om Prakash, et al.
Publicado: (2021)

India's COVID-19 vaccination drive: key challenges and resolutions
por: Choudhary, Om Prakash, et al.
Publicado: (2021)

SARS-CoV-2 vaccine breakthrough reinfection in a health-care worker of Iraq: A case report
por: Hasan, Dlshad Abdullah, et al.
Publicado: (2022)

Immunomodulatory and therapeutic implications of vitamin D in the management of COVID-19
por: Dhawan, Manish, et al.
Publicado: (2022)

Booster vaccination is required to elicit and maintain COVID-19 vaccine-induced immunity in SIV-infected macaques
por: Li, Pingchao, et al.
Publicado: (2023)

Intranasal COVID-19 vaccines: Is it a boon or bane?
por: Choudhary, Om Prakash, et al.
Publicado: (2021)

Trajectory of COVID-19 vaccine hesitancy post-vaccination and public’s intention to take booster vaccines: A cross-sectional analysis
por: Salman, Muhammad, et al.
Publicado: (2023)

Emerging heterologous mRNA-based booster strategies within the COVID-19 vaccine landscape
por: Das, Rituparna, et al.
Publicado: (2023)

Bivalent second booster dose of the COVID-19 vaccine: Eligible populations’ reasons for receiving in Italy
por: Della Polla, Giorgia, et al.
Publicado: (2023)

Global discrimination of COVID-19 vaccine
por: Sohil, Fariha, et al.
Publicado: (2022)

The association between adverse events of COVID-19 vaccination and anxiety and willingness to receive a booster dose
por: Chen, Liling, et al.
Publicado: (2023)

COVID-19 vaccine booster dose hesitancy among key groups: A cross-sectional study
por: Huang, Min, et al.
Publicado: (2023)

Is public negligence driving India towards the third wave of COVID-19?
por: Choudhary, Om Prakash, et al.
Publicado: (2021)

Tracking the COVID-19 vaccines: The global landscape
por: Yadav, Tushar, et al.
Publicado: (2023)

Protective immunity against COVID-19: Unravelling the evidences for humoral vs. cellular components
por: Priyanka, et al.
Publicado: (2021)

Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine
por: Yong, Xiaolan, et al.
Publicado: (2023)

Coverage of primary and booster vaccination against COVID-19 by socioeconomic level: A nationwide cross-sectional registry study
por: Hansen, Bo T., et al.
Publicado: (2023)

Heterologous mRNA-based COVID-19 booster strategies: Comment
por: Yasri, Sora, et al.
Publicado: (2023)

Evolution of SARS-CoV-2: A prediction on the lineages and vaccine effectiveness
por: Priyanka, et al.
Publicado: (2021)

Pediatricians’ perspectives on COVID-19 and HPV vaccine hesitancy
por: Ryan, Grace W., et al.
Publicado: (2023)

Real-life effectiveness of COVID-19 vaccine during the Omicron variant-dominant pandemic: how many booster doses do we need?
por: Sritipsukho, Paskorn, et al.
Publicado: (2023)

Author reply to “Heterologous mRNA-based COVID-19 booster strategies: Comment”
por: Das, Rituparna, et al.
Publicado: (2023)

Heterologous booster with inhaled adenovirus vector COVID-19 vaccine generated more neutralizing antibodies against different SARS-CoV-2 variants
por: Zhong, Jiaying, et al.
Publicado: (2022)

Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines
por: Kyaw, Moe H., et al.
Publicado: (2023)

A case–case study on the effect of primary and booster immunization with China-produced COVID-19 vaccines on prevention of pneumonia and viral load among vaccinated persons infected by Delta and Omicron variants
por: Wu, Dan, et al.
Publicado: (2022)

Immunogenicity and safety of single booster dose of KD-414 inactivated COVID-19 vaccine in adults: An open-label, single-center, non-randomized, controlled study in Japan
por: Terada-Hirashima, Junko, et al.
Publicado: (2023)

Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults
por: Costa Clemens, Sue Ann, et al.
Publicado: (2023)

Effectiveness of a booster dose of COVID-19 vaccines during an outbreak of SARS-CoV-2 Omicron BA.2.2 in China: A case–control study
por: Zhang, Xiaqing, et al.
Publicado: (2023)

“In general people aren’t excited about the vaccine…”: Frontline perspectives on COVID-19 vaccine hesitancy across Syria
por: Alhaffar, Mervat, et al.
Publicado: (2023)

Chatting with ChatGPT to learn about safety of COVID-19 vaccines – A perspective
por: Salas, Antonio, et al.
Publicado: (2023)

Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies
por: Wang, Xun, et al.
Publicado: (2022)

Second wave of COVID-19 in India: Dissection of the causes and lessons learnt
por: Choudhary, Om Prakash, et al.
Publicado: (2021)

Heterologous Omicron-adapted vaccine as a secondary booster promotes neutralizing antibodies against Omicron and its sub-lineages in mice
por: Liu, Jianyang, et al.
Publicado: (2022)

An omicron-based vaccine booster elicits potent neutralizing antibodies against emerging SARS-CoV-2 variants in adults
por: Li, Tao, et al.
Publicado: (2023)

India and the COVID-19 vaccine
por: Satish, Karthyayani Priya
Publicado: (2022)

A nasal omicron vaccine booster elicits potent neutralizing antibody response against emerging SARS-CoV-2 variants
por: Lam, Joy-Yan, et al.
Publicado: (2022)

Comparable antigen-specific T cell responses in vaccinees with diverse humoral immune responses after the primary and booster BBIBP-CorV vaccination
por: Wei, Dong, et al.
Publicado: (2022)

Heterologous prime-boost vaccination against COVID-19: is it safe and reliable?
por: Choudhary, Om Prakash, et al.
Publicado: (2021)

Addressing COVID-19 vaccine hesitancy
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cq5nv5s3odkaqajqkbedri55he